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of subjects victims of alopecia. Furthermore, 18.2% suf-
fer from anxiety, 3,5% presented a social phobia and
4,4% paranoia. All these rates are above those noticed
with the general population. CONCLUSION: These dif-
ferent results underline the necessity for assessing the psy-
chological and even psychiatric consequences of hair loss
for patients suffering alopecia. Demonstration is done
that these patients need to have a relevant psychological
help from their practitioners, who are very often them-
selves relying on the outside help of a pharmacological
nature for assisting their work.
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OBJECTIVE: A single course of treatment with Assisted
Reproduction Techniques (ART) may be viewed as in-
complete treatment for the majority of infertile couples.
A realistic comparison of both costs and therapeutic con-
sequences must consider the cumulative costs of achiev-
ing an ongoing pregnancy after several cycles of treat-
ment using Recombinant FSH (rFSH) or urinary FSH
(uFSH). METHOD: A cost-effectiveness analysis included
the Markov model and Monte-Carlo simulations. Infor-
mation on costs and probabilities were provided by na-
tional formulary costs and clinic tariff, a meta-analysis
(of randomized clinical trials), randomized controlled
clinical trials, medical literature and national registries.
All the data were validated by a panel of international ex-
perts. Because estimates for key clinical data will vary de-
pending on the source, the estimates of variability among
the transition probabilities were ratified by the expert
panel according to UK experience. This approach pro-
vided a distribution of transition probabilities from which
a precise standard deviation could be obtained for each
outcome. The final Markov matrix included about 200
health states, computerized with a specific Pascal pro-
gram, which covered the complete ART process includ-
ing both fresh and cryopreserved embryos. RESULTS:
After running 5000 simulations on a virtual population
of 100,000 patients the results are: Total number of suc-
cesses (pregnancy): 40,575 for rFSH and 37,358 for
uFSH. Cost/success: £5906 (SD  £232) for rFSH and
£6060 (SD  £279) for uFSH. Mean number of cycles/
success: 4.59 for rFSH and 5.25 for uFSH. CONCLU-
SION: Recombinant FSH is more effective and more
cost-effective than urinary derived FSH.
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OBJECTIVE: To identify the quality of life (QoL) dimen-
sions relevant for men who currently take sildenafil to
treat erectile dysfunction (ED) and to evaluate the impact
of sildenafil use on these QoL dimensions. QoL studies
can be a valuable tool for healthcare decision-makers as
they assess the relative benefits and costs of sildenafil
treatment for ED. METHODS: 500 men taking sildenafil
were interviewed, using a structured questionnaire specif-
ically developed for this study. Each had been diagnosed
with ED by a physician. The respondents were asked to
rate the extent to which sildenafil had affected both phys-
ical and emotional aspects of their life. RESULTS: Fifty-
two percent had been taking sildenafil for more than 1
year. Eighty-six percent of the participants were married.
Of the remaining 14%, 69% reported being in a commit-
ted relationship. The overall results indicate that QoL
measures were high in men receiving sildenafil. The re-
spondents (average age 62) reported that the QoL dimen-
sions where sildenafil had the most impact were confi-
dence, relationship with partner, sex life, and life overall.
Sixty percent reported that they felt more confident after
treating their ED with sildenafil. Eighty-two percent re-
ported an improvement in their relationships with part-
ners; 75% reported an improvement in their sex lives;
and 66% reported an improvement in their overall lives.
CONCLUSION: The results suggest that use of sildenafil
to treat ED has a positive impact on patient’s lives. The re-
sults also suggest that additional investigation into identi-
fying relevant QoL items and domains for ED is war-
ranted since this impact has been undetected by currently
available QoL instruments.
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OBJECTIVE: The scoring of the Women’s Health Ques-
tionnaire (WHQ) was reviewed as part of the Interna-
tional Health-related Quality of Life Database (IQOD)
program. New hypotheses on item grouping were con-
firmed in different translated versions of the WHQ. Using
this new conceptual model, reference values were devel-
oped per country and in different populations. METHODS:
The scoring of the WHQ was reviewed using data from
different countries: UK, US, France, Germany, Italy, Po-
land. The 23-item WHQ measures QoL in women, and
